Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

Next generation KRAS inhibitor divarasib significantly extends lung cancer survival (opens in a new tab)

news-medical.net · 2026-10-26

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

17 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims
3

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

The literature search

17 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 13 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 5Not checkedPatients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer lived significantly longer and had improved disease control when treated with divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 5Not checkedThe global phase 3 Krascendo 1 study was published in The New England Journal of Medicine and presented at the European Society for Medical Oncology Congress 2026; it was led by principal investigator Ferdinandos Skoulidis.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 5Not checkedResearchers compared divarasib with currently approved KRAS G12C inhibitors sotorasib or adagrasib in NSCLC patients whose cancer had progressed after prior treatment.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 5Not checkedTreatment with divarasib reduced the risk of disease progression by 42% and the risk of death by 44%, and median overall survival improved to 17.7 months versus 12 months with sotorasib/adagrasib.View evidenceHide evidence

As stated42% lower progression risk; 44% lower death risk; median overall survival 17.7 vs 12 months

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 5Not checkedThe article says divarasib also improved progression-free survival, response rate, duration of response, and tolerability versus current KRAS-targeted therapies, and it notes limitations including the open-label design and exclusion of patients with untreated brain metastases.View evidenceHide evidence

As statedmedian progression-free survival 9.8 vs 5.7 months; overall response rate 58.4% vs 32.3%; duration of response 11.9 vs 6.9 months; severe treatment-related side effects 25% vs 35%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

Pharmacometric analysis of pharmacokinetics, safety, and efficacy data of migoprotafib in combination with divarasib for KRAS G12C-positive non-small cell lung cancer.

Pharmacometric Analysis of Pharmacokinetics, Safety, and Efficacy Data of Migoprotafib in Combination with Divarasib for KRAS G12C-positive Non-small Cell Lung Cancer. · 2026 · Crossref

Source (opens in a new tab)

Explore all search results